GoldenGolden
Advanced Search
Geneos Therapeutics

Geneos Therapeutics

Geneos Therapeutics is a plasmid-based Neoantigen-targeted Cancer Therapies.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

March 3, 2021
Geneos Therapeutics secures $12,000,000 in Series A1 Financing led Global Bio Fund with strong participation from all existing Series A investors including, notably, Santé Ventures and Inovio Pharmaceuticals.
February 2019
Geneos Therapeutics raises a $10,500,000 series A round from Inovio Pharmaceuticals and Sante Ventures.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Geneos Therapeutics, Inc.
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer,...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.